drugset / Trial / NCT04084080
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Phase 3
Active not recruiting
173 enrolled
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Timeline
- Start
- 2020-02-26
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Red Blood Cell | Unknown | — | — |